This review highlights some recent advances in the design and development of matrix metalloproteinase inhibitors, especially
those targeting MMP-2, MMP-9, and MMP-13. Various zinc-binding groups and non-zinc-binding groups are discussed. Interactions between
residues in the critical S1' specificity pocket and MMP inhibitors are given special attention. The influence of ionization states of
hydroxamates and retrohydroxamates on the docking outcome and the presence of zinc ions in the active site are explored in light of enhancing
enrichment factors for docking studies. Details are given to structural factors for the development of more selective and more potent
Keywords: MMP-2, MMP-3, MMP-13, rheumatoid arthritis, osteoarthritis, cancer, docking, and zinc binding group.
Rights & PermissionsPrintExport